Category: Lindner Center of HOPE News

Return to news >

Research Institute at Lindner Center of HOPE, in affiliation with the University of Cincinnati, College of Medicine, is conducting a Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness), research study to compare the effectiveness of two medications used to treat bipolar disorder.

February 24, 2011 – Mason, OH – The Research Institute at Lindner Center of HOPE, in affiliation with the University of Cincinnati, College of Medicine, is conducting a Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness) research study to compare the effectiveness of two medications used to treat bipolar disorder. The study evaluates the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic medication, compared to lithium, a universally recognized medication used to treat bipolar disorder.

With Massachusetts General Hospital leading the 10-site study, Lindner Center of HOPE is recruiting study participants for assessment and appropriateness of participation. Bipolar disorder, a lifelong and highly recurrent mood disorder, causes patients to experience alternating episodes of major depression and mania/hypomania. It is among the top 10 causes of disability worldwide with associated costs of $70.6 billion per year for treatment and prevention.

Susan L. McElroy, MD“Research studies and the advances they lead to will be closely integrated into the evidence-based treatment programs provided at Lindner Center of HOPE,” say Susan L. McElroy, MD, Chief Research Officer, Lindner Center of HOPE. “The validity of studies evaluating genuine life-experiences can reveal data that is critical to clinical treatment decisions.” This research is designed to inform health care decisions by providing evidence and information on the effectiveness, benefits and harms of different treatment options.

Over the past 10 years, the pharmacologic treatments for bipolar disorder have shifted away from lithium in favor of newly developed antipsychotics, such as quetiapine. Both medications have well documented side effects. Quetiapine has the risk of drowsiness and weight gain. Weight gain may increase the risk of cardiovascular disease. Lithium is associated with the risk of long-term thyroid and kidney problems.

Bipolar CHOICE is funded by a $10 million grant from the Agency for Healthcare Research Quality and is part of an investment made under the American Recovery and Reinvestment Act of 2009. The Act designated $1.1 billion to support patient-centered outcomes research.

Potential study participants can call Dianna Moeller at (513) 536-0707 or information can be found at www.lindnercenterofhope.org/research.

About Lindner Center of HOPE:
Lindner Center of HOPE provides patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, free-standing mental health center and charter member of the National Network of Depression Centers, the Center provides psychiatric hospitalization for individuals age 11-years-old and older, outpatient services for all ages, research and voluntary, live-in services. The Center’s clinicians are ranked among the best providers locally, nationally and internationally. Lindner Center of HOPE is affiliated with the University of Cincinnati (UC) College of Medicine.

Contact: Jennifer Pierson
(513) 536-0316
[email protected]

Return to news >

Lindner Center of HOPE created some brief videos to help families know when behaviors may be more than teen angst.

Adolescence and early adulthood are critical times when physical, cognitive, and social changes allow a teenager to develop the identity that will serve as a basis for their adult lives. Research has indicated that psychiatric illnesses frequently present during the adolescent years, thereby making early diagnosis and effective treatment even more crucial.

Treatment For Teen Depression

Changes in Adolescents That May Cause Concern

Information on Teenager Angst & Depression

Return to news >

Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced results from a 24-week open-label study demonstrating that treatment with Contrave(R) resulted in significant improvements in depressive symptoms that was accompanied by weight loss and improved control of eating in overweight and obese patients with major depression.

Mason, OH – July 1, 2010– “This study is the first step in assessing the value of Contrave in this important patient population and these positive results should encourage additional investigation,” said Susan McElroy, MD, Lindner Center of HOPE.

Read the press release, click here.

About the Lindner Center of HOPE:
Lindner Center of HOPE provides patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, free-standing mental health center, Lindner Center of HOPE is a charter member of the National Network of Depression Centers. The Center provides psychiatric hospitalization for individuals age 11-years-old and older, outpatient services for all ages, research, voluntary live-in services, partial hospitalization programs, Transcranial Magnetic Stimulation (TMS), diagnostic imaging and first-class amenities to patients suffering from mood disorders, anxiety disorders, schizophrenia and related illnesses, eating and weight disorders, ADHD and substance use conditions. The Center employs a stellar multidisciplinary team that utilizes years of experience and evidence-based treatments to partner with patients and families to reach positive outcomes. The Lindner Center of HOPE is affiliated with the University of Cincinnati (UC) College of Medicine. The Center, which began serving patients and families on August 18, 2008, is a non-profit mental health care provider located in Mason, Ohio.

Contact:

Jennifer Pierson
Lindner Center of HOPE
(513) 536-0316
[email protected]

Return to news >

Mason, OH –September 2009 – Lindner Center of HOPE introduced a groundbreaking new treatment for patients with major depression beginning in August 2009. Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment that uses electromagnetic energy to stimulate the area of the brain that is linked to depression.

As a charter member of the National Network of Depression Centers, Lindner Center of HOPE is the only regional facility to offer NeuroStar TMS, which was recently cleared by the U.S. Food and Drug Administration (October 2008) for the treatment of major depression. TMS therapy was demonstrated to be effective and safe in the treatment of depressed patients that failed to receive adequate benefit from prior antidepressant medication and counseling.

The treatment is a 40-minute outpatient procedure that is prescribed by a psychiatrist, does not require anesthesia or sedation, and patients remain awake and alert. The treatment is typically administered daily for 4 to 6 weeks and the patient is able to maintain their normal routine before and after treatment.

“We are excited to be providing TMS therapy and to be a part of this major step forward in the treatment of depression,” said Dallas Auvil, MD, Lindner Center of HOPE psychiatrist. “Now we have a new option that may significantly improve the quality of life for depressed patients who have not had previous success with antidepressants and counseling.”

Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. Each year, over 30,000 people in the United States commit suicide, 60 percent of whom suffer from depression. The economic burden of depression in 2000 was estimated at $83.1 billion in the United States.

Depression can be devastating. Only a fraction of individuals suffering from depression seek treatment, and unfortunately, out of the numbers that opt for treatment, greater than 30 percent fail to achieve satisfactory improvement. Therefore, a tremendous unmet need exists in the Cincinnati area and the region for new treatment options for major depression.

Read more about TMS Therapy, click here.

For more information about the Lindner Center of HOPE and TMS treatment, call 513-536-0537 or 1-888-537-4229.

About Lindner Center of HOPE:

Lindner Center of HOPE provides patient-centered, scientifically-advanced care for individuals suffering with mental illness. The newest state-of-the-science, free-standing mental health center to be built in North America, the Center is a charter member of the National Network of Depression Centers. The Center provides psychiatric hospitalization for individuals age 11-years-old and older, outpatient services for all ages, research and voluntary, live-in services in the Sibcy House. The Center’s clinicians are ranked among the best providers locally, nationally and internationally. Lindner Center of HOPE is affiliated with the University of Cincinnati (UC) College of Medicine, and will be opening a new Brain Imaging Center with a 3.0 Tesla MRI, the best in the world, in January 2010 for diagnostic and research purposes.

Contact:
Susan Sherman

(513) 536 -0510

[email protected]